Skip to main content
OpenTrials
Completed

NCT Number: NCT06479382

Study of the ETX-4143 2.0 Device in Subjects With Eye Pain

A prospective early-feasibility study to evaluate the safety and effectiveness of the ETX-4143 2.0 device. The device is intended to treat subjects with eye pain

Completed

Looking for future studies?

Notify Me

Key information

Age range

22 year–90 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Westmead Hospital, Westmead, New South Wales, Australia

Loading trial locations.

About this study

A prospective early-feasibility study to evaluate the safety and effectiveness of the ETX-4143 2.0 device. The device is intended to treat subjects who suffer from eye pain an do not get relieve from current medications or clinical treatments. Thirty eyes will be enrolled and randomized 2:1 to the investigational treatment or a sham treatment. Improvement in self-reported ocular pain and clinical safety measures will be evaluated.

It is anticipated that the learnings from the study will be used to design future study of the ETX-4143 2.0 device.

All subjects will be followed for 8 weeks. Subjects will only have the worse eye treated if both eyes meet the inclusion/exclusion criteria.

A medical monitor will evaluate the safety of the study on a continual basis.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Documented history of eye pain with no relief from currently available medications or treatments
  • Willing to forgo participation in any other clinical stud for the duration of this study
  • Demonstrate sufficient cognitive awareness to comply with the examination process
  • Willing and able to comply with the schedule for follow-up visits
  • Willing to participate in the study as evidenced by signing an informed consent document

Exclusion criteria

  • Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study time period, including the follow-up period
  • Any active ocular infection or active ocular inflammation at the time of the screening visit
  • History of herpes keratitis, non-healing corneal epithelial defects, or neurotrophic keratopathy due to corneal herpetic disease, stem cell deficiency, diabetic keratopathy, severe lagophthalmos, or topical anesthetic abuse
  • Any history of significant eye surgery with the prior 90 days
  • Planned eye surgery during the entire study
  • Participation in any clinical study of an investigational product within 30 days prior to enrollment
  • Any history of serious, poorly controlled systemic or ophthalmic condition that could compromise the subject's ability to comply with the protocol or compromise their safety

Treatment and study plan

ETX-4143 2.0

Device

Treatment of the eye with the ETX-4143 2.0 device

Primary outcomes

  1. Reduction of eye pain

    Time frame: Eight weeks

    Patient reported level of eye pain

  2. Adverse events

    Time frame: Eight weeks

    Adverse events related to treatment

Sponsors and collaborators

Lead sponsor

EyeCool Therapeutics, Inc.

Industry

Registry information

Official study title

A Prospective Early-Feasibility Study to Evaluate the Safety and Effectiveness of ETX-4143 2.0 Device in Subjects With Eye Pain

Important dates

Study start
2024
Primary completion
2024
Study completion
2024
First posted
Jun 28, 2024
Registry last updated
Aug 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.